Why is Verastem shifting focus after its pancreatic cancer trial results?

Verastem Oncology decided to redirect its R&D focus after updated data for its avutometinib and defactinib combination in first-line metastatic pancreatic cancer showed only modest benefit. The company views this as a pragmatic move, aiming to pursue programs with stronger efficacy potential and better commercial or regulatory prospects within its portfolio.